Search results for: Jennifer Litton

Items from 1 to 19 out of 19 results

article

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, more

Breast Cancer Research > 2019 > 21 > 1 > 1-12

Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation. Methods The primary endpoint was objective response rate (ORR). Secondary endpoints were 6-month progression-free...

article

Severe hyponatremia following cyclophosphamide infusion in breast cancer patients

Katherine Clifton, Chad Barnett, Ashley Martinez, Meghan Karuturi, more

The Breast Journal > 24 > 4 > 691 - 692

article

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Katherine Clifton, Angelica Gutierrez-Barrera, Junsheng Ma, Roland Bassett, more

Breast Cancer Research and Treatment > 2018 > 170 > 1 > 101-109

Purpose As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported conflicting results in overall survival in patients receiving neoadjuvant or adjuvant systemic therapy. This study aims to analyze outcomes of adjuvant versus...

article

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey Ager, Matthew Reilley, Courtney Nicholas, Todd Bartkowiak, more

Journal for ImmunoTherapy of Cancer > 2016 > 4 > 1 > 107-221

article

Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer

Grace Tran, Monica Helm, Jennifer Litton

Current Breast Cancer Reports > 2016 > 8 > 3 > 165-174

Risk reduction strategies for women at an increased risk for breast cancer include prophylactic mastectomy, prophylactic salpingo-oophorectomy, and chemoprevention. These techniques have been well studied in certain high-risk populations such as women with significant family histories of breast cancer and women with BRCA1 and BRCA2 mutations. Rapid evolution in genetic testing technology has enabled...

article

Genotype–Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers

Soley Bayraktar, Michelle Jackson, Angelica M. Gutierrez‐Barrera, Diane Liu, more

The Breast Journal > 21 > 3 > 260 - 267

The genotype–phenotype correlations of the specific BRCA1 and BRCA2 mutations in multi‐ethnic populations in USA have not yet been fully investigated. This study was designed to evaluate the effects of ethnicity at specific mutation locations and breast/ovarian cancer phenotypes. Our cohort included 445 women with different ethnic backgrounds who underwent BRCA genetic testing between 1997 and 2010...

article

Hereditary breast cancer syndromes and genetic testing

Thereasa A. Rich, Ashley H. Woodson, Jennifer Litton, Banu Arun

Journal of Surgical Oncology > 111 > 1 > 66 - 80

Only 5% of breast cancers are explained by highly penetrant multisystem autosomal dominant hereditary disorders. Though another 20–30% has a familial presentation, the genetic and other etiologies are still not well understood. Genetic testing is now widely available and multiple professional societies have published guidelines for testing and management. Genetic testing trends include utilization...

article

Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2

Sarah A. Jackson, Andrew A. Davis, Jun Li, Nengjun Yi, more

Cancer > 120 > 10 > 1557 - 1564

BACKGROUNDLarge rearrangements in BRCA1 and BRCA2 occur in a small percentage (< 1%) of patients tested for hereditary breast (BC) and ovarian cancer. It is unclear what factors predict BRACAnalysis Large Rearrangement Test (BART) positivity. METHODSData from 6 centers were included in this analysis. Individuals with negative Comprehensive BRACAnalysis tested for BART were included. RESULTSFrom...

article

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André, Ruth O'Regan, Mustafa Ozguroglu, Masakazu Toi, more

The Lancet Oncology > 2014 > 15 > 6 > 580-591

Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab. In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with...

article

Tamoxifen therapy for patients with breast cancer

Jennifer Litton, Aman Buzdar, Mariana Chavez Mac Gregor, Ana Gonzalez-Angulo, more

The Lancet > 2013 > 381 > 9883 > 2077-2078

article

Genotype in BRCA‐associated Breast Cancers

Funda Meric‐Bernstam, Angelica M. Gutierrez‐Barrera, Jennifer Litton, Lauren Mellor‐Crummey, more

The Breast Journal > 19 > 1 > 87 - 91

Women with BRCA1 or 2 mutations are at high risk for breast cancer. For BRCA1, a trend of increasing risk has been associated with increasing downstream (3′) location for mutations compared to the upstream (5′) mutations in the gene. For BRCA2, an increased risk of breast cancer has been associated with mutations outside of the ovarian cancer cluster region (OCCR). We sought to determine the mutation...

article

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ

Soley Bayraktar, Nisreen Elsayegh, Angelica M. Gutierrez Barrera, Heather Lin, more

Cancer > 118 > 6 > 1515 - 1522

BACKGROUND:It is unclear whether women with ductal carcinoma in situ (DCIS), like their counterparts with invasive breast cancer, warrant genetic risk assessment and testing on the basis of high‐risk variables. The authors of this report identified predictive factors for mutations in the breast cancer‐susceptibility genes BRCA1 and BRCA2 in women who were diagnosed with DCIS. METHODS:One hundred...

article

Bisphosphonates and pathologic complete response to taxane‐ and anthracycline‐based neoadjuvant chemotherapy in patients with breast cancer

Mariana Chavez‐MacGregor, Erika Brown, Xiudong Lei, Jennifer Litton, more

Cancer > 118 > 2 > 326 - 332

BACKGROUND:Several studies have suggested that bisphosphonates have an antitumor effect. In the current study, the authors sought to evaluate whether the use of bisphosphonates increased the rate of pathological complete response (pCR) in patients with breast cancer. METHODS:The authors identified 1449 patients with breast cancer who were receiving taxane‐ and anthracycline‐based neoadjuvant chemotherapy...

article

Expression and Relevance of TRPS-1: A New GATA Transcription Factor in Breast Cancer

Jie Qing Chen, Yi Bao, Jennifer Litton, Li Xiao, more

Hormones and Cancer > 2011 > 2 > 2 > 132-143

GATA transcription factor family members have been found to play a critical role in the differentiation of many tissue types. For example, GATA-3 has been found to be highly correlated with estrogen receptor α (ER) expression and is emerging as one of the “master regulators” in breast ductal epithelial cell differentiation. Recently, we discovered another GATA family member highly prevalent in breast...

article

Pathologic complete response in breast cancer patients receiving anthracycline‐ and taxane‐based neoadjuvant chemotherapy

Mariana Chavez‐MacGregor, Jennifer Litton, Huiqin Chen, Sharon H. Giordano, more

Cancer > 116 > 17 > 4168 - 4177

BACKGROUND:The current study was conducted to evaluate the influence of race/ethnicity and tumor subtype in pathologic complete response (pCR) following treatment with neoadjuvant chemotherapy. METHODS:A total of 2074 patients diagnosed with breast cancer between 1994 and 2008 who were treated with neoadjuvant anthracycline‐ and taxane‐based chemotherapy were included. pCR was defined as no residual...

article

Clinicopathologic Factors Associated With Involved Margins After Breast-Conserving Surgery for Invasive Lobular Carcinoma

Eric J. Silberfein, Kelly K. Hunt, Kristine Broglio, Jeannie Shen, more

Clinical Breast Cancer > 2010 > 10 > 1 > 52-58

Obtaining negative margins for patients undergoing breast-conserving surgery (BCS) for invasive lobular carcinoma (ILC) can be difficult because of the unique histologic pattern of ILC. Our goal was to determine whether any specific patient- or disease-related factors influenced margin status. We retrospectively reviewed 211 patients with ILC treated from 1994 through 2004 to determine if specific...

article

Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer

Jie Qing Chen, Jennifer Litton, Li Xiao, Hua-Zhong Zhang, more

Hormones and Cancer > 2010 > 1 > 1 > 21-33

The trichorhinophalangeal syndrome 1 (TRPS-1) gene is a novel GATA transcription factor family member. Previously, using a gene expression profiling and immunohistochemistry (IHC) screen, we identified TRPS-1 as a highly prevalent gene in breast cancer (BC), expressed in >90% of estrogen receptor alpha (ERα)⁺ and ERα⁻ BC subtypes. TRPS-1 was also shown to be expressed in prostate cancer where it...

article

Breast Cancer Before Age 40 Years

Carey K. Anders, Rebecca Johnson, Jennifer Litton, Marianne Phillips, more

Seminars in Oncology > 2009 > 36 > 3 > 237-249

Approximately 7% of women with breast cancer are diagnosed before the age of 40 years, and this disease accounts for more than 40% of all cancer in women in this age group. Survival rates are worse when compared to those in older women, and multivariate analysis has shown younger age to be an independent predictor of adverse outcome. Inherited syndromes, specifically BRCA1 and BRCA2, must be considered...

article

Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

Yesim Eralp, Terry L. Smith, Kadri Altundağ, Shu-Wan Kau, more

Journal of Cancer Research and Clinical Oncology > 2009 > 135 > 1 > 141-148

Background There is scarce data on the outcome of young patients aged 35 years and younger, who have been treated with neoadjuvant chemotherapy. The aim of this study is to evaluate the impact of body mass index (BMI) and various prognostic factors on pathologic response and survival in young patients with localized breast cancer. Patients and methods This is a retrospective evaluation on the outcome...

Filter options

Publication date

Set your own date range

INFONA - science communication portal

Search results for: Jennifer Litton

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options